At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, UK, explains that the development of immunotherapies for a variety of cancer types and specific cancer proteins is a very active area of research at Sarah Cannon Research Institute.
New trials for cancer patients at Sarah Cannon Research Institute
9 Feb 2018
Oncology
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.